Inpatient Healthcare Resource Utilization, Costs, and Mortality in Adult Patients With Acute Graft-Versus-Host Disease, Including Steroid-Refractory or High-Risk Disease, Following Allogeneic Hematopoietic Cell Transplantation

Abstract Acute graft-versus-host disease (GVHD) contributes to poor outcomes following allogeneic hematopoietic cell transplantation (HCT). Data are limited regarding the economic burden of acute GVHD, particularly steroid-refractory or high-risk (SR/HR) disease. This retrospective analysis of the Premier Healthcare Database reports inpatient healthcare resource utilization (HCRU), costs, and mortality during initial hospitalization for allogeneic HCT and through 100 days post-HCT among patients who developed acute GVHD, including a subgroup with SR/HR disease, compared with patients with no GVHD. The analysis included adults discharged for first HCT between January 1, 2011, and June 30, 2016 (acute GVHD, n=906; SR/HR acute GVHD, n=158; no GVHD, n=1529). During the initial hospitalization for HCT, patients with acute GVHD and SR/HR acute GVHD (n=455 and n=125, respectively) had significantly longer median lengths of stay (31 and 46 vs 24 days) and higher median total costs ($153,849 and $205,880 vs $97,417) versus patients with no GVHD (n=1529; all P